Hunter disease is an X-linked lysosomal storage disorder characterized by progressive storage of glycosaminoglycans (GAGs) and multi-organ impairment. The central nervous system (CNS) is involved in at least 50% of cases. Since 2006, the enzymatic replacement therapy (ERT) is available but with no effect on the cognitive impairment, as the present formulation does not cross the blood-brain barrier. Here we report the outcome of 17 Hunter patients treated in a single center. Most of them (11) started ERT in 2006, 3 had started it earlier in 2004, enrolled in the phase III trial, and 3 after 2006, as soon as the diagnosis was made. The liver and spleen sizes and urinary GAGs significantly decreased and normalized throughout the treatment. Heart parameters improved, in particular the left ventricular mass index/m<sup>2</sup> decreased significantly. Amelioration of hearing was seen in many patients. Joint range of motion improved in all patients. However, no improvement on respiratory function, eye, skeletal and CNS disease was found. The developmental quotient of patients with a CNS involvement showed a fast decline. These patients were no more testable after 6 years of age and, albeit the benefits drawn from ERT, their quality of life worsened throughout the years. The whole group of patients showed a consistent residual disease burden mainly represented by persistent skeletal disease and frequent need of surgery. This study suggests that early diagnosis and treatment and other different therapies which are able to cross the blood-brain barrier, might in the future improve the MPS II outcome.

Parini, R., Rigoldi, M., Tedesco, L., Boffi, L., Brambilla, A., Bertoletti, S., et al. (2015). Enzymatic replacement therapy for Hunter disease: Up to 9 years experience with 17 patients. MOLECULAR GENETICS AND METABOLISM REPORTS, 3, 65-74 [10.1016/j.ymgmr.2015.03.011].

Enzymatic replacement therapy for Hunter disease: Up to 9 years experience with 17 patients

Brambilla, A;Gaini, R;Gallone, D;Giussani, C;Grimaldi, M;Messinesi, G;Nichelli, F;Sganzerla, E;Valsecchi, G;Biondi, A
2015

Abstract

Hunter disease is an X-linked lysosomal storage disorder characterized by progressive storage of glycosaminoglycans (GAGs) and multi-organ impairment. The central nervous system (CNS) is involved in at least 50% of cases. Since 2006, the enzymatic replacement therapy (ERT) is available but with no effect on the cognitive impairment, as the present formulation does not cross the blood-brain barrier. Here we report the outcome of 17 Hunter patients treated in a single center. Most of them (11) started ERT in 2006, 3 had started it earlier in 2004, enrolled in the phase III trial, and 3 after 2006, as soon as the diagnosis was made. The liver and spleen sizes and urinary GAGs significantly decreased and normalized throughout the treatment. Heart parameters improved, in particular the left ventricular mass index/m2 decreased significantly. Amelioration of hearing was seen in many patients. Joint range of motion improved in all patients. However, no improvement on respiratory function, eye, skeletal and CNS disease was found. The developmental quotient of patients with a CNS involvement showed a fast decline. These patients were no more testable after 6 years of age and, albeit the benefits drawn from ERT, their quality of life worsened throughout the years. The whole group of patients showed a consistent residual disease burden mainly represented by persistent skeletal disease and frequent need of surgery. This study suggests that early diagnosis and treatment and other different therapies which are able to cross the blood-brain barrier, might in the future improve the MPS II outcome.
Articolo in rivista - Articolo scientifico
Enzymatic replacement therapy; ERT; Hunter disease; Hunter syndrome; Idursulfase; MPS II; Mucopolysaccharidosis type II; Endocrinology; Genetics; Molecular Biology
English
65
74
10
Parini, R., Rigoldi, M., Tedesco, L., Boffi, L., Brambilla, A., Bertoletti, S., et al. (2015). Enzymatic replacement therapy for Hunter disease: Up to 9 years experience with 17 patients. MOLECULAR GENETICS AND METABOLISM REPORTS, 3, 65-74 [10.1016/j.ymgmr.2015.03.011].
Parini, R; Rigoldi, M; Tedesco, L; Boffi, L; Brambilla, A; Bertoletti, S; Boncimino, A; Del Longo, A; De Lorenzo, P; Gaini, R; Gallone, D; Gasperini, S; Giussani, C; Grimaldi, M; Grioni, D; Meregalli, P; Messinesi, G; Nichelli, F; Romagnoli, M; Russo, P; Sganzerla, E; Valsecchi, G; Biondi, A
File in questo prodotto:
File Dimensione Formato  
Hunter Disease.pdf

Solo gestori archivio

Dimensione 1.8 MB
Formato Adobe PDF
1.8 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/140932
Citazioni
  • Scopus 54
  • ???jsp.display-item.citation.isi??? 55
Social impact